[go: up one dir, main page]

MX2015012318A - Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. - Google Patents

Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.

Info

Publication number
MX2015012318A
MX2015012318A MX2015012318A MX2015012318A MX2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A
Authority
MX
Mexico
Prior art keywords
solid state
state forms
quinazoline derivative
braf inhibitor
application
Prior art date
Application number
MX2015012318A
Other languages
English (en)
Inventor
Martin J Jacobs
Stephen J Bierlmaier
Ralph C Haltiwanger
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MX2015012318A publication Critical patent/MX2015012318A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta solicitud se refiere a varias sales y formas de estado sólido del Compuesto (I) La solicitud también se refiere a composiciones farmacéuticas y usos farmacéuticos de estos materiales y composiciones.
MX2015012318A 2013-03-11 2014-03-11 Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. MX2015012318A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776081P 2013-03-11 2013-03-11
PCT/US2014/023110 WO2014164648A2 (en) 2013-03-11 2014-03-11 Solid state forms of a quinazoline derivative and its use as a braf inhibitor

Publications (1)

Publication Number Publication Date
MX2015012318A true MX2015012318A (es) 2016-04-15

Family

ID=50771322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012318A MX2015012318A (es) 2013-03-11 2014-03-11 Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.

Country Status (15)

Country Link
US (3) US9353097B2 (es)
EP (1) EP2956454A2 (es)
JP (1) JP2016512516A (es)
KR (1) KR20150132118A (es)
CN (1) CN105051039A (es)
AU (2) AU2014249158B2 (es)
BR (1) BR112015022207A8 (es)
CA (1) CA2901204C (es)
EA (1) EA025561B1 (es)
HK (2) HK1217333A1 (es)
IL (1) IL241239A0 (es)
MX (1) MX2015012318A (es)
NZ (1) NZ710600A (es)
TW (1) TW201512192A (es)
WO (1) WO2014164648A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025561B1 (ru) 2013-03-11 2017-01-30 Игнита, Инк. Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111153860B (zh) * 2019-12-30 2021-06-29 广州六顺生物科技股份有限公司 一种喹唑啉类化合物的晶型及其制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
NZ587907A (en) 2008-03-17 2012-09-28 Ambit Biosciences Corp Quinazoline derivatives as RAF kinase modulators and methods of use thereof
AU2012240240A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
EA025561B1 (ru) 2013-03-11 2017-01-30 Игнита, Инк. Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf

Also Published As

Publication number Publication date
BR112015022207A2 (pt) 2017-07-18
WO2014164648A2 (en) 2014-10-09
AU2016204294A1 (en) 2016-07-14
EP2956454A2 (en) 2015-12-23
AU2016204294B9 (en) 2017-09-21
IL241239A0 (en) 2015-11-30
BR112015022207A8 (pt) 2018-01-23
US9353097B2 (en) 2016-05-31
WO2014164648A4 (en) 2015-01-29
EA025561B1 (ru) 2017-01-30
CA2901204A1 (en) 2014-10-09
EA201591259A1 (ru) 2016-02-29
AU2014249158A1 (en) 2015-09-17
HK1217333A1 (zh) 2017-01-06
AU2016204294B2 (en) 2017-08-31
CN105051039A (zh) 2015-11-11
US9987281B2 (en) 2018-06-05
KR20150132118A (ko) 2015-11-25
CA2901204C (en) 2018-07-10
JP2016512516A (ja) 2016-04-28
TW201512192A (zh) 2015-04-01
US9718810B2 (en) 2017-08-01
NZ710600A (en) 2017-01-27
AU2014249158B2 (en) 2016-07-28
US20170290833A1 (en) 2017-10-12
HK1217193A1 (zh) 2016-12-30
US20160280698A1 (en) 2016-09-29
US20150376171A1 (en) 2015-12-31
WO2014164648A3 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
NZ716840A (en) Combination formulation of two antiviral compounds
HK1220355A1 (zh) Mk2抑制劑和其用途
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
UA116239C2 (uk) Нові похідні піридину
MY176797A (en) Novel pyrazol derivatives
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
UA115357C2 (uk) Похідні піридин-4-ілу
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
EA201270728A1 (ru) Пуриновые соединения
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
HK1221645A1 (zh) Vmat2的苯并喹啉抑制剂